GLP-1

News

Novo Nordisk’s semaglutide aces another outcomes trial

Novo Nordisk has halted a phase 3 trial of its Ozempic formulation of GLP-1 agonist semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) early aft

News

EMA probes suicide risk with Novo Nordisk obesity drugs

The European Medicines Agency (EMA) has started a review of two Novo Nordisk drugs used to treat obesity and those overweight, following reports of suicidal thoughts or se

News

CHMP backs obesity drug Wegovy for teens

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

News

close up of a prescription bottle with white tables falling out on top of a group of hundred dollar bills

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri

News

AstraZeneca improves diabetes pen to maintain its market sha...

The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduct

News

Novo's diabetes pill beats injections in head-to-head trials

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market.

Novo Nordisk’s semaglutide aces another outcomes trial

EMA probes suicide risk with Novo Nordisk obesity drugs

CHMP backs obesity drug Wegovy for teens

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

AstraZeneca improves diabetes pen to maintain its market sha...

Novo's diabetes pill beats injections in head-to-head trials

Alzheimer's biotech Korsana to go public via reverse merger

Using AI-driven synthetic personas to take your insights fur...

GLP-1

Editor's Picks